Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population

Weaker Effects of the Fourth Dose of BNT162b2 SARS-CoV-2 Vaccine on the Elderly Human Population

The vaccines presently available are less effective in older people due to senescence of their immune systems. We measured the antibody responses of 42 adults living in nursing homes after the third and the fourth doses of an mRNA vaccine and found that the strain (BA.2 and BA.2.75: from 64 to 128,...

Full description

Bibliographic Details
Main Authors:	Chloé Dimeglio, Isabelle Da-Silva, Marion Porcheron, Marie-Pierre Panero, Laetitia Staes, Pauline Trémeaux, Hélène Villars, Jacques Izopet
Format:	Article
Language:	English
Published:	MDPI AG 2023-06-01
Series:	Vaccines
Subjects:	vaccination vulnerable population SARS-CoV-2 immune monitoring
Online Access:	https://www.mdpi.com/2076-393X/11/6/1095

Similar Items

Study of the cellular and humoral immune responses to SARS-CoV-2 vaccination
by: Faustine Montmaneix-Engels, et al.
Published: (2024-04-01)

Decreased Efficiency of Neutralizing Antibodies from Previously Infected or Vaccinated Individuals against the B.1.617.2 (Delta) SARS-CoV-2 Variant
by: Chloé Dimeglio, et al.
Published: (2022-08-01)

Antibody Titers and Protection against Omicron (BA.1 and BA.2) SARS-CoV-2 Infection
by: Chloé Dimeglio, et al.
Published: (2022-09-01)

Influence of the Delta Variant and Vaccination on the SARS-CoV-2 Viral Load
by: Marion Migueres, et al.
Published: (2022-02-01)

Influence of a Heterologous (ChAdOx1-nCoV-19/BNT162b2) or Homologous (BNT162b2/BNT162b2) Vaccination Regimen on the Antibody and T Cell Response to a Third Vaccination with BNT162b2
by: Rieke Reiter, et al.
Published: (2022-05-01)

Will the latest wave of the COVID‐19 pandemic be an ecological disaster? There is an urgent need to replace plastic by ecologically virtuous materials
by: Jean‐Michel Mansuy, et al.
Published: (2022-09-01)

Influence of SARS-CoV-2 Variant B.1.1.7, Vaccination, and Public Health Measures on the Spread of SARS-CoV-2
by: Chloé Dimeglio, et al.
Published: (2021-05-01)

Humoral and T-Cell Response before and after a Fourth BNT162b2 Vaccine Dose in Adults ≥60 Years
by: Erez Bar-Haim, et al.
Published: (2022-05-01)

Longitudinal Analysis of SARS-CoV-2-Specific Cellular and Humoral Immune Responses and Breakthrough Infection following BNT162b2/BNT162b2/BNT162b2 and ChAdOx1/ChAdOx1/BNT162b2 Vaccination: A Prospective Cohort in Naive Healthcare Workers
by: Geon Young Ko, et al.
Published: (2023-10-01)

Immunogenicity and SARS-CoV-2 Infection following the Fourth BNT162b2 Booster Dose among Health Care Workers
by: Yael Shachor-Meyouhas, et al.
Published: (2023-01-01)

Pseudo-Anaphylactic Reactions to Pfizer BNT162b2 Vaccine: Report of 3 Cases of Anaphylaxis Post Pfizer BNT162b2 Vaccination
by: Xin Rong Lim, et al.
Published: (2021-08-01)

Response Rate of the Third and Fourth Doses of the BNT162b2 Vaccine Administered to Cancer Patients Undergoing Active Anti-Neoplastic Treatments
by: Abed Agbarya, et al.
Published: (2023-09-01)

Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
by: Michal Canetti, et al.
Published: (2022-12-01)

Analysis of Immunization, Adverse Events, and Efficacy of a Fourth Dose of BNT162b2 Vaccine in Health Workers in Mexico, a Pilot Study
by: Maria Elena Romero-Ibarguengoitia, et al.
Published: (2022-07-01)

High Immune Response Rate to the Fourth Boost of the BNT162b2 Vaccine against the Omicron Variants of Concern among Liver Transplant Recipients
by: Yana Davidov, et al.
Published: (2022-12-01)

Omicron Wave SARS-CoV-2 Diagnosis: Evaluation of Saliva, Anterior Nasal, and Nasopharyngeal Swab Samples
by: Marion Migueres, et al.
Published: (2022-12-01)

Association between Reactogenicity and Immunogenicity after Vaccination with BNT162b2
by: Stilla Bauernfeind, et al.
Published: (2021-09-01)

Author Correction: Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up
by: Michal Canetti, et al.
Published: (2023-03-01)

Immunogenicity of the third and fourth BNT162b2 mRNA COVID-19 boosters and factors associated with immune response in patients with SLE and rheumatoid arthritis
by: Wonngarm Kittanamongkolchai, et al.
Published: (2022-07-01)

Longitudinal cellular and humoral immune responses after triple BNT162b2 and fourth full-dose mRNA-1273 vaccination in haemodialysis patients
by: Matthias Becker, et al.
Published: (2022-10-01)

Effectiveness of the BNT162b2 and the CoronaVac vaccines and boosters in healthcare workers
by: Hazal Cansu Çulpan, et al.
Published: (2023-12-01)

BNT162b2 COVID-19 Vaccination and Its Effect on Blood Pressure
by: Toh Leong Tan, et al.
Published: (2022-12-01)

Extended interval BNT162b2 vaccination enhances peak antibody generation
by: Helen Parry, et al.
Published: (2022-01-01)

Humoral response after BNT162b2 vaccine in Japanese hemodialysis patients
by: Ryoichi Miyazaki, et al.
Published: (2023-02-01)

Spontaneous pneumomediastinum after BNT162b2 COVID-19 vaccination in adolescents
by: Chi-Yan Lam, et al.
Published: (2023-07-01)

Efficacy of BNT162b2 and CoronaVac in patients diagnosed with COVID-19
by: Dogan Mustafa, et al.
Published: (2023-06-01)

Myopericarditis following both BNT162b2 and NVX-CoV2373
by: Saima Ahmad, et al.
Published: (2022-12-01)

Immune-Mediated Thrombotic Thrombocytopenic Purpura after BNT162b2 Vaccine
by: Tekin Guney, et al.
Published: (2022-02-01)

A racing heart post‐Pfizer/BioNTech BNT162b2
by: Hooi Khee Teo, et al.
Published: (2022-10-01)

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021
by: Francesca Fortunato, et al.
Published: (2023-01-01)

Immunogenicity and reactogenicity of a third dose of BNT162b2 vaccine for COVID-19 after a primary regimen with BBIBP-CorV or BNT162b2 vaccines in Lima, Peru.
by: Natalia Vargas-Herrera, et al.
Published: (2022-01-01)

Prediction of SARS-CoV-2 Variant Lineages Using the S1-Encoding Region Sequence Obtained by PacBio Single-Molecule Real-Time Sequencing
by: Sébastien Lhomme, et al.
Published: (2021-12-01)

Correlates of protection for booster doses of the SARS-CoV-2 vaccine BNT162b2
by: Tomer Hertz, et al.
Published: (2023-07-01)

Durable immune responses after BNT162b2 vaccination in home-dwelling old adults
by: Lena Hansen, et al.
Published: (2023-04-01)

Evaluation of Two-Month Antibody Levels after Heterologous ChAdOx1-S/BNT162b2 Vaccination Compared to Homologous ChAdOx1-S or BNT162b2 Vaccination
by: Simone Barocci, et al.
Published: (2022-03-01)

Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine
by: Payne, RP, et al.
Published: (2021)

Analysis of intracranial haemorrhage following tozinameran (BNT162b2, Pfizer-BioNTech)
by: Yohhei Hamada
Published: (2021-12-01)

Risk of carditis among adolescents after extending the interdose intervals of BNT162b2
by: Min Fan, et al.
Published: (2024-02-01)

Cost-effectiveness analysis of COVID-19 booster vaccination with BNT162b2 in Japan
by: Mitsuhiro Nagano, et al.
Published: (2024-12-01)

P1584: CELLULAR IMMUNE RESPONSE TO THE BNT162B2 VACCINE IN LYMPHOMA PATIENTS
by: R. Gurion, et al.
Published: (2022-06-01)